Anorectal Transition Zone Stem Cells for Fistula Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for perianal fistulas, particularly in Crohn's disease patients, are ineffective in durably healing the condition, with existing therapies leading to temporary symptom relief and side effects, and existing scaffolding products often cause abscess formation or spontaneous expulsion.
Innovation Solution
The use of isolated anorectal transition zone (ATZ) cells, which are multipotent stem cells or progenitor cells, combined with a biocompatible scaffold, to treat fistulas by promoting tissue regeneration and closure, with the cells being allogeneic or autologous and capable of differentiating into endodermal, mesodermal, or ectodermal cells, and being cryopreserved for use in pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If volume-retaining scaffolding products (fibrin glue, porcine plugs) are used to infill the fistula tract, then the tract is filled and symptoms are reduced, but the products are prone to eliciting abscess formation and spontaneous expulsion
Solution Approach 1:
The patent uses a biocompatible scaffold as an intermediary carrier to deliver isolated ATZ cells to the fistula tract. The scaffold provides structural support while the ATZ cells actively promote tissue regeneration, creating a synergistic effect that overcomes the limitations of passive scaffolding products alone.
Solution Approach 2:
The isolated ATZ cells possess intrinsic tissue regenerative capacity and can differentiate into endodermal, mesodermal, and ectodermal cells. These cells autonomously promote healing of the fistula tract without requiring external intervention, converting the passive scaffolding approach into an active self-healing system.
2Ease of operation
If antibiotics, immunosuppressants, and TNF-alpha inhibitors are used to reduce symptoms, then symptom relief is achieved, but the treatments have side effects and unsatisfactory therapeutic outcomes with limited duration
Solution Approach 1:
The isolated ATZ cells autonomously promote tissue regeneration and healing through their intrinsic regenerative capacity and differentiation potential. This self-service mechanism eliminates the need for continuous pharmacological intervention, providing durable therapeutic outcomes without the side effects associated with long-term antibiotic, immunosuppressant, or TNF-alpha inhibitor use.
3Reliability
If allogeneic adipose-derived mesenchymal stem cells are injected directly in tissue along the fistula tract, then additional benefit is achieved over placebo control, but the effect is not statistically significant after one year of follow-up
Solution Approach 1:
The ATZ cells are isolated, characterized, and expanded in vitro before being formulated with a biocompatible scaffold for implantation. This preliminary preparation ensures the cells are in an optimal state for transplantation, maximizing their regenerative potential and ensuring sustained therapeutic effect beyond one year.
Solution Approach 2:
The patent combines isolated ATZ cells with a biocompatible scaffold to create a composite therapeutic product. This composite approach provides both structural support from the scaffold and active regenerative function from the ATZ cells, creating a synergistic effect that extends therapeutic benefit beyond what either component could achieve alone.
Data Source
AI summary
Provided herein are compositions of anorectal transition zone stem cells, including multipotent and progenitor cells, to treat anal fistulas, for example, refractory complex perianal fistulas associated with Crohn's disease or of unknown aetiology. Also provided are pharmaceutical compositions of the anorectal transition zone stem cells, including multipotent and progenitor cells, in a pharmaceutically acceptable carrier.